Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (140)

2024

  1. Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

    Pain and Therapy

2023

  1. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

  2. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  3. Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine

    Neurology and Therapy, Vol. 12, Núm. 4, pp. 1319-1334

  4. Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence

    Geburtshilfe und Frauenheilkunde, Vol. 84, Núm. 2, pp. 164-184

  5. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

    Clinical Lung Cancer, Vol. 24, Núm. 5, pp. 415-428

  6. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

    ESMO Open, Vol. 8, Núm. 4

2022

  1. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    npj Breast Cancer, Vol. 8, Núm. 1

  2. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  3. Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain

    Patient Preference and Adherence, Vol. 16, pp. 3291-3302

  4. Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients

    Journal of Psychiatric Research, Vol. 145, pp. 302-308

  5. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192

  6. Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

    Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077

  7. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

    Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141

  8. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  9. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

    Nature communications, Vol. 13, Núm. 1, pp. 1878

  10. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy - Reply

    JAMA Oncology

  11. Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  12. Treatment with Adjuvant Abemaciclib Plus Endocrine Therapy in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 8, pp. 1190-1194

  13. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64